Efficacy of humanized anti-BCMA CAR-T cell therapy in relapsed/refractory multiple myeloma patients with and without extramedullary disease
Haobin Deng1 , Meijing Liu1 , Ting Yuan2,3 , huan Zhang2,3 , Rui Cui2,3 , Jingyi Li2,3 , Jijun Yuan4 , xiaofang Wang5 , Yafei Wang5 , qi Deng2,3
1. The First Central Clinical College of Tianjin Medical University, Tianjin, China.
2. Department of Hematology, Tianjin First Central Hospital
3. School of Medicine, Nankai University
4. Shanghai Genbase Biotechnology Co., Ltd. Shanghai, China.
5. Department of Hematology, Tianjin Medical University Cancer Institute and Hospital. Tianjin, China.
To observe and compare the efficacy and safety of humanized anti-B cell maturation antigen (anti-BCMA) chimeric antigen receptor (CAR) T-cell therapy in relapsed/refractory (R/R) multiple myeloma (MM) patients with and without extramedullary disease. Seven R/R MM patients with extramedullary disease and thirteen patients without extramedullary disease enrolled in humanized anti-BCMA-CAR T cell therapy. The ORR had no difference in patients with and without extramedullary disease. There was no difference of PFS and OS in two group of R/R MM patients at 180 days, but the PFS and OS in the patients with extramedullary disease were lower at 360 days. When the disease of some patients with extramedullary disease progressed again, the M protein level did not increase at the same time. But it was not seen in patients without extramedullary disease. In patients obtained ORR reaction, the grades of cytokine release syndrome (CRS) and Immune effector cell associated neurotoxic syndrome (ICANS) were much higher in patients with extramedullary disease group. R/R MM patients with extramedullary disease could benefit from humanized anti-BCMA-CAR T cell therapy in short-term as patients without extramedullary disease. The grades of CRS and ICANS were much higher in these patients.
(ChiCTR1800017051 and ChiCTR2000033925)
